Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA meeting on epinephrine

This article was originally published in The Tan Sheet

Executive Summary

FDA announces a Dec. 5 public meeting to solicit comments on a proposed rule to amend the agency's regulation on the use of ozone-depleting substances in self-pressurized containers to "remove the essential-use designation for oral pressurized metered-dose inhalers containing epinephrine." In addition, the comment period on the proposed rule published in September is being extended to Dec. 19, FDA says (1"The Tan Sheet" Sept. 24, 2007, p. 7). Meeting attendees must register by Nov. 23, according to the agency...

You may also be interested in...



Primatene Mist To Be Unavailable After 2010 – Proposed Rule

Wyeth will allow its epinephrine-containing Primatene Mist metered-dose inhaler to be phased out of the market after 2010, rather than reformulating to comply with an FDA proposed rule published in the Sept. 20 Federal Register

QUOTED. 28 January 2020. Steven Falowski.

Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

Topics

UsernamePublicRestriction

Register

PS101088

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel